Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Regen BioPharma Inc RGBP

Regen BioPharma Inc. is a biotechnology company. The Company is engaged on the immunology and immunotherapy space. The Company is focused on novel technologies through pre-clinical and Phase I/ II clinical trials. It is involved on mRNA and small molecule therapies for treating cancer and autoimmune disorders. It is also developing products treating blood disorders using small molecules and... see more

Recent & Breaking News (OTCPK:RGBP)

Cancer Clinical Trials Expert Dr. Santosh Kesari to Assist Regen BioPharma, Inc. in Addressing FDA Questions Regarding Planned dCellVax Immunotherapy Clinical Trial for Breast Cancer

PR Newswire June 10, 2015

Regen BioPharma, Inc. Recruits Retinoid Experts Dr. Hinrich Gronemeyer, Dr. William S. Blaner, and Dr. Louise Purton to Serve on Scientific Advisory Board

Marketwired June 4, 2015

Regen BioPharma Files Patent Application on mRNA Dendritic Cell Cancer Immunotherapeutic

Marketwired May 27, 2015

Regen BioPharma, Inc. Makes Three Presentations at the 13th International Symposium on Myelodysplastic Syndromes Held April 29 to May 2, 2015 in Washington, DC

Marketwired May 5, 2015

Regen BioPharma Sees Opportunities Resulting from AACR Conference Attendance and Presentation

Marketwired April 27, 2015

Regen BioPharma, Inc. Engages Charles River Laboratories to Initiate FDA-Requested Study to Support Initiation of HemaXellerate Clinical Trial

Marketwired April 22, 2015

Regen BioPharma Recruits Renowned Cancer Stem Cell Experts to Scientific Advisory Board

Marketwired April 16, 2015

Regen BioPharma Narrows Selection of CRO Candidates for HemaXellerate GLP Safety Studies Requested by the FDA

Marketwired April 13, 2015

Regen BioPharma Inc. Announces Small Molecule Drug Discovery Milestones at the American Association for Cancer Research's 2015 Annual Meeting

Marketwired April 9, 2015

Regen BioPharma Inc. to Present Multiple Presentations at the 13th International Symposium on Myelodysplastic Syndromes

Marketwired April 7, 2015

Regen BioPharma Expands Its Differentiation Therapy of Cancer Stem Cells Platform With Filing of Patent Applications on Silencing of NR2F2

Marketwired April 6, 2015

Regen BioPharma CEO Discusses Recent Financings, New Laboratory Facilities and Preferred Stock Dividend

Marketwired April 1, 2015

Regen BioPharma Announces Presentation of DiffronC at Cold Spring Harbor Conference on RNA & Oligonucleotide Therapeutics

Marketwired March 31, 2015

Regen BioPharma, Inc. Expands Research Capacity With New Laboratory Facilities

Marketwired March 24, 2015

Regen Receives Green Light From FDA to Proceed With GLP Safety Study in Support of Its HemaXellerate Investigational New Drug Application

Marketwired March 17, 2015

Regen BioPharma Acquires Issued Patent and Preclinical Data Package for Targeting Cancer Stem Cell

Marketwired March 10, 2015

Regen BioPharma Inc. Files Patent Application for Treatment of Myelodysplastic Syndrome Utilizing Gene Silencing Therapy

Marketwired March 3, 2015

Regen BioPharma Inc. Announces Preferred Stock Dividend

Marketwired February 24, 2015

Regen BioPharma, Inc. Comments on dCellVax Cancer IDO-Targeting Technology in Relation to Bristol Myers Squibb-Flexus Biosciences, Inc. Announcement

Marketwired February 24, 2015

Regen BioPharma, Inc. Expands Management Team With the Addition of New CFO Todd Caven

Marketwired February 17, 2015